Analysts Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $4.25

Mersana Therapeutics, Inc. (NASDAQ:MRSN) has earned an average recommendation of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $4.25.

A number of equities analysts recently issued reports on MRSN shares. Wedbush reissued an “outperform” rating and set a $4.00 price target on shares of Mersana Therapeutics in a report on Monday, March 3rd. William Blair initiated coverage on Mersana Therapeutics in a report on Thursday, February 6th. They issued an “outperform” rating on the stock.

Institutional Investors Weigh In On Mersana Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. US Bancorp DE acquired a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at approximately $31,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at approximately $34,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Mersana Therapeutics during the 4th quarter valued at approximately $37,000. Intech Investment Management LLC acquired a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at approximately $52,000. Finally, Quarry LP acquired a new stake in shares of Mersana Therapeutics during the 3rd quarter valued at approximately $57,000. Hedge funds and other institutional investors own 93.92% of the company’s stock.

Mersana Therapeutics Stock Performance

NASDAQ MRSN opened at $0.46 on Thursday. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a 52-week low of $0.45 and a 52-week high of $5.11. The business’s 50-day moving average price is $0.64 and its 200 day moving average price is $1.50. The firm has a market cap of $57.94 million, a P/E ratio of -0.76 and a beta of 1.67.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. The firm had revenue of $16.36 million for the quarter, compared to analyst estimates of $7.71 million. On average, equities research analysts expect that Mersana Therapeutics will post -0.62 earnings per share for the current year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.